Join our daily newsletter At The Bell to receive exclusive market insights
- Emyria (EMD) receives further positive MDMA analogue screening results
- The company has been progressing its ecstasy analogue development program, which is being run in partnership with the University of Western Australia
- The results bring the total count of successfully screened MDMA analogues to date to 83 out of 85
- Additional preclinical screenings are now being planned with a leading research organisation who will perform assays to evaluate the solubility, partition coefficients and metabolic stability of each compound
- Emyria climbs 6 per cent, trading at 26.5 cents
Emyria (EMD) has received further positive MDMA analogue screening results.
The company has been progressing its ecstasy analogue development program, which is being run in partnership with the University of Western Australia.
16 out of 17 compounds sent from the second batch of analogues passed screening with Eurofins at the test concentrations. This means these compounds showed no evidence of interactions with one or more of the enzymes or cell receptors that can be associated with unwanted clinical side effects.
These results bring the total count of successfully screened MDMA analogues to date to 83 out of 85.
Additional preclinical screenings are now being planned with a leading research organisation, who will perform a number of assays to evaluate the solubility, partition coefficients and metabolic stability of each compound.
The company said these assays can help to predict absorption and brain uptake rates and help identify compounds that are similar to MDMA in potency, but with faster onset and shorter half-lives, which may be more suitable for clinical applications.
“We are now planning pivotal preclinical studies to help identify which of these compounds may have the potency of common MDMA but with enhanced safety and shorter acting times and half-lives,” Managing Director Michael Winlo said.
“We anticipate this screening program will help identify compounds with the potential to become registered treatments for other neuropsychiatric conditions,” Dr Winlo added.
Emyria climbed 6 per cent, trading at 26.5 cents at 3:59 pm AEST.
